Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756898 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 370
- Enrollment target
NCT01756898: Completed Phase 2 study, sponsored by Daiichi Sankyo.
NCT01756898 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 370 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (178% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01756898, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 370 participants
- Enrollment target
Study Summary
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.
Primary Outcome
Participants with an IGA score of 0 or 1 were considered IGA responders. The investigator provided an overall assessment of disease severity using the IGA, which consists of a 6-point scale from a minimum of 0 and a maximum of 6. Higher scores indicate a worse outcome and lower scores indicate a better outcome. (0 = clear; 1 = almost clear; 2 = mild disease; 3 = moderate disease, 4 = severe disease; and 5 = very severe disease).
Interventions
- DRUG Placebo
- DRUG 5 mg ASB17061
- DRUG 10 mg ASB17061
- DRUG 20 mg ASB17061
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2012-11-28 |
| Est. Completion | 2014-01-14 |
| Phase | Phase 2 |
What the finished NCT01756898 record still lists
NCT01756898 is an interventional study that assigns participants to a tested intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (178% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01756898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01756898 about?
NCT01756898 is a clinical study titled "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis". The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.
What is the current status of trial NCT01756898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 370 participants. The study started on 2012-11-28. Estimated completion is 2014-01-14.
What interventions are being tested in trial NCT01756898?
The interventions under investigation include: Placebo (DRUG), 5 mg ASB17061 (DRUG), 10 mg ASB17061 (DRUG), 20 mg ASB17061 (DRUG).
Who is sponsoring clinical trial NCT01756898?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01756898's enrollment target sits among peer trials
370 120th of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI